The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMUX | -31.13% | -96.16% | -47.89% | -97% |
| S&P | +13.66% | +87.02% | +13.34% | +130% |
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | 4.8% |
| Market Cap | $86.97M | -41.5% |
| Market Cap / Employee | $0.96M | 0.0% |
| Employees | 91 | 18.2% |
| Net Income | -$25.58M | -5.0% |
| EBITDA | -$25.95M | -1.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $35.13M | -40.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.13M | -32.3% |
| Short Term Debt | $0.67M | -6.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -195.41% | -48.3% |
| Return On Invested Capital | -211.93% | -95.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.21M | 3.1% |
| Operating Free Cash Flow | -$20.14M | 3.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.19 | 5.33 | -11.89 | 2.56 | 9.70% |
| Price to Tangible Book Value | 2.19 | 5.33 | -11.89 | 2.56 | 9.70% |
| Enterprise Value to EBITDA | -2.17 | -3.63 | -1.40 | -5.26 | 24.10% |
| Return on Equity | -424.4% | -246.3% | -208.9% | -398.5% | 84.28% |
| Total Debt | $1.00M | $0.98M | $0.98M | $0.79M | -11.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
